| Symbol | ALEC |
|---|---|
| Name | ALECTOR, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 131 OYSTER POINT BLVD.,SUITE 600, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 415 231-5660 |
| Fax | — |
| — | |
| Website | https://www.alector.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001653087 |
| Description | Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline product inlcude AL001, AL002, AL003, and AL101. Additional info from NASDAQ: |
Yaffe Kristine 🟢 acquired 38.1K shares (1 derivative) of Alector, Inc. (ALEC) Transaction Date: Jun 17, 2026 | Filing ID: 274134
Read moreSCHELLER RICHARD H 🟢 acquired 38.1K shares (1 derivative) of Alector, Inc. (ALEC) Transaction Date: Jun 17, 2026 | Filing ID: 274128
Read moreHammond Paula 🟢 acquired 38.1K shares (1 derivative) of Alector, Inc. (ALEC) Transaction Date: Jun 17, 2026 | Filing ID: 274131
Read moreGAROFALO ELIZABETH A. 🟢 acquired 38.1K shares (1 derivative) of Alector, Inc. (ALEC) Transaction Date: Jun 17, 2026 | Filing ID: 274132
Read moreAltmeyer Mark 🟢 acquired 38.1K shares (1 derivative) of Alector, Inc. (ALEC) Transaction Date: Jun 17, 2026 | Filing ID: 274124
Read moreDESOUZA ERROL B 🟢 acquired 38.1K shares (1 derivative) of Alector, Inc. (ALEC) Transaction Date: Jun 17, 2026 | Filing ID: 274123
Read moreLAVIGNE LOUIS J JR 🟢 acquired 38.1K shares (1 derivative) of Alector, Inc. (ALEC) Transaction Date: Jun 17, 2026 | Filing ID: 274120
Read moreSCHELLER RICHARD H 🟢 acquired 10.8K shares of Alector, Inc. (ALEC) Transaction Date: Jun 01, 2026 | Filing ID: 255990
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07105709 | Open-label Extension Study in Participants With Early Alzheimer's Disease | Phase2 | Alzheimer's Disease | Recruiting | 2025-08-14 | 2028-12-08 | ClinicalTrials.gov |
| NCT06111014 | Continuation Study for Latozinemab | Phase3 | Neurodegenerative Diseases | Terminated | 2023-12-08 | 2026-01-07 | ClinicalTrials.gov |
| NCT06079190 | Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer'… | Phase2 | Alzheimer's Disease | Active_Not_Recruiting | 2023-10-20 | 2026-11-23 | ClinicalTrials.gov |
| NCT05744401 | A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of A… | Phase2 | Alzheimer's Disease | Terminated | 2023-01-04 | 2025-02-05 | ClinicalTrials.gov |
| NCT05053035 | A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS | Phase2 | Amyotrophic Lateral Sclerosis | Terminated | 2021-09-02 | 2022-10-28 | ClinicalTrials.gov |
| NCT04592874 | A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With E… | Phase2 | Alzheimer Disease | Completed | 2021-01-22 | 2024-09-12 | ClinicalTrials.gov |
| NCT04374136 | A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Deme… | Phase3 | Frontotemporal Dementia | Terminated | 2020-07-23 | 2026-01-06 | ClinicalTrials.gov |
| NCT04111666 | A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101 | Phase1 | Healthy | Completed | 2019-12-14 | 2022-06-09 | ClinicalTrials.gov |
| NCT03987295 | A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal … | Phase2 | Frontotemporal Dementia | Completed | 2019-09-27 | 2024-06-05 | ClinicalTrials.gov |
| NCT03822208 | First in Human Study for Safety and Tolerability of AL003. | Phase1 | Healthy | Completed | 2019-03-29 | 2021-05-06 | ClinicalTrials.gov |
| NCT03635047 | A Phase I Study for Safety and Tolerability of AL002. | Phase1 | Healthy | Completed | 2018-11-12 | 2020-11-25 | ClinicalTrials.gov |
| NCT03636204 | A First in Human Study in Healthy Volunteers and in Participants With Frontotem… | Phase1 | Healthy | Completed | 2018-09-14 | 2019-12-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03636204 |
| AL001 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03636204 |
| Saline Solution | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03635047 |
| AL002 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03635047 |
| Saline Solution | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03822208 |
| AL003 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03822208 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04111666 |
| AL101 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04111666 |
| Placebo | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT05053035 |
| AL001 | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT05053035 |
| Latozinemab | Other | Phase PHASE3 | Neurodegenerative Diseases | TERMINATED | NCT06111014 |
| Placebo | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT04592874 |
| AL002 | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT04592874 |
| Placebo | Other | Phase PHASE2 | Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT06079190 |
| GSK4527226 | Other | Phase PHASE2 | Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT06079190 |
| AL001 | Other | Phase PHASE2 | Frontotemporal Dementia | COMPLETED | NCT03987295 |
| Open label - AL001 | Other | Phase PHASE3 | Frontotemporal Dementia | TERMINATED | NCT04374136 |
| Placebo | Other | Phase PHASE3 | Frontotemporal Dementia | TERMINATED | NCT04374136 |
| AL001 | Other | Phase PHASE3 | Frontotemporal Dementia | TERMINATED | NCT04374136 |
| GSK4527226 | Other | Phase PHASE2 | Alzheimer's Disease | RECRUITING | NCT07105709 |
| AL002 | Other | Phase PHASE2 | Alzheimer's Disease | TERMINATED | NCT05744401 |
| Latozinemab | DRUG | Phase PHASE3 | Neurodegenerative Diseases | TERMINATED | NCT06111014 |
| GSK4527226 | DRUG | Phase PHASE2 | Alzheimer's Disease | RECRUITING | NCT07105709 |
| Open label - AL001 | DRUG | Phase PHASE3 | Frontotemporal Dementia | TERMINATED | NCT04374136 |
| AL101 | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT04111666 |
| AL003 | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT03822208 |
| Placebo | OTHER | Phase PHASE2 | Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT06079190 |
| AL001 | DRUG | Phase PHASE2 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT05053035 |
| Saline Solution | OTHER | Phase PHASE1 | Healthy | COMPLETED | NCT03822208 |
| AL002 | DRUG | Phase PHASE2 | Alzheimer's Disease | TERMINATED | NCT05744401 |